凝血酶激活的纤溶抑制物基因多态性及其与血栓性疾病关系的研究进展
摘要
凝血酶激活的纤溶抑制物（thrombin-activatable fibrinolysis inhibitor，TAFI）属于金属羧肽酶家族成员，最初于1989年由Hendriks等首先在血清中发现，Boffa和Koschinsky于1995年发现TAFI被凝血酶激活后具有抑制纤溶酶的活性，且证明它与之前不同命名的血浆羧基肽酶原B、羧基肽酶原U和羧基肽酶原R为同一物质，现已统一命名为TAFI。
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2008年第9期1066-1069,共4页
Chinese Journal of Laboratory Medicine
参考文献32
-
1Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem, 2007, 40 :431-442.
-
2Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood ,2001,97 : 2053-2058.
-
3Frere C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost, 2005, 94:373- 379.
-
4Frere C, Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood, 2006,108 : 1562-1568.
-
5Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene.. relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica, 2001,86:510-517.
-
6Bladbjerg EM, de Maat MP, Christensen K, et al. Genetic influence on thrombotic risk markers in the elderly--a Danish twin study. J Thromb Haemost, 2006,4:599-607.
-
7Morange PE, Henry M,Frere C, et al. Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction. Blood, 2002,99 : 1878-1879.
-
8Schneider M, Boffa M, Stewart R, et al. Two naturally occurring variants of TAFI ( Thr-325 and Ile-325 ) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem, 2002, 277:1021-1030.
-
9Ceresa E, Van de Borne K, Peeters M, et al. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J Biol Chem,2006,281 : 15878-15883.
-
10Peetz D, Victor A, Adams P, et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost, 2004,92:344-351.
-
1周发为.慢性肝病患者血浆中凝血酶激活的纤溶系统检测的临床意义[J].临床血液学杂志（输血与检验）,2013,26(4):546-548. 被引量：2
-
2蔡文玮,盛净.凝血酶激活的纤溶抑制物(TAFI)研究进展[J].微循环技术杂志（临床与实验）,2004,8(5):326-329.
-
3许延路,高辉,李继福,徐从高.冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析[J].血栓与止血学,2009,15(5):211-212. 被引量：2
-
4张鑫,沈志滨.凝血酶激活的纤溶抑制物的临床应用进展[J].重庆医学,2010,39(23):3276-3278. 被引量：2
-
5蒋晨成,孔英君,李世敏.凝血酶激活的纤溶抑制物与肺部疾病的关系[J].国际呼吸杂志,2014,34(24):1895-1899.
-
6付锴,饶莉.血管紧张素转换酶2与动脉粥样硬化的关系[J].西部医学,2012,24(3):614-615. 被引量：1
-
7苑德才.关于流行性出血热统一命名及译名的规定[J].口岸卫生控制,2000,5(1):43-43.
-
8谢丹.血尿酸与胰岛素抵抗的相关性[J].第四军医大学学报,2005,26(1):82-82.
-
9侯文广,刘克强.凝血酶激活的纤溶抑制物:开启防治血栓性疾病的新思路[J].临床荟萃,2006,21(19):1429-1431.
-
10许延路,王淑廷,朱媛媛,李继福,徐从高.冠心病合并糖尿病患者血浆中凝血酶激活的纤溶抑制物变化[J].血栓与止血学,2010,16(3):113-114. 被引量：1
